麻豆视频

Global Diabetic Retinopathy Market Trends and Insights

Rising Global Diabetes Prevalence & Earlier Screening

International Federation of Diabetes data foresee 12% of the world鈥檚 adults living with diabetes by 2045, enlarging the treatable pool for the diabetic retinopathy market ^{[1]International Diabetes Federation, 鈥淚DF Diabetes Atlas,鈥� idf.org}. Meta-analyses confirm disease rates above 22% in multiple screening programs, underlining a consistent burden across regions. AI tools that deliver 92-93% sensitivity now detect micro-aneurysms at routine primary-care visits, shifting diagnosis to earlier, more treatable stages. Chile鈥檚 national tele-ophthalmology network cut specialist referrals to 15% while preserving coverage, showing scalable early detection in lower-resource settings.

Aging Population Increasing Vision-Threatening Cases

Patients with more than 10 years of diabetes carry 4.36-fold higher odds of retinopathy, and most are over 60 years old. China reports prevalence between 24.7% and 43.1%, highlighting the aging-duration nexus in the region. Female patients have shown bigger increases in blindness, suggesting the need for gender-specific care strategies. Vitrectomy demand mirrors these trends, expanding 8.14% annually as elderly patients present with complex proliferative disease.

Expanding Indications & Reimbursement for Long-Acting Anti-VEGF Biologics

Five U.S. aflibercept biosimilars secured FDA approval in 2024, creating downward price pressure and broader payer coverage. Genentech鈥檚 Susvimo received clearance for continuous delivery with two refills a year, and Regeneron鈥檚 Eylea HD is under priority review for longer dosing intervals, both directly addressing the 46% break-off rate seen in diabetic macular edema.

AI-Enabled Retinal Screening Adoption in Primary-Care Clinics

AEYE Health won FDA clearance for the first fully autonomous AI algorithm that needs only one image per eye, achieving 99% imageability and over 92% sensitivity. Less than 5% of U.S. diabetics accessed AI screening between 2019-2023, leaving substantial headroom for expansion. India鈥檚 plan to scan 1 billion eyes over 10 years illustrates the scalability of AI combined with low-cost handheld cameras. Real-world Czech data show AI outperforms general ophthalmologists in sensitivity while raising follow-up adherence by 89%.

Shortage of Retinal Specialists in Emerging Markets

The United States is projected to face a 12% fall in ophthalmologist supply versus a 24% rise in demand by 2035, and rural counties may meet only 26-29% of their staffing need ^{[2]American Academy of Ophthalmology, 鈥淥phthalmologist Workforce Projections,鈥� aaojournal.org} . Asia-Pacific shows even sharper gaps as diabetic prevalence climbs faster than specialist training, prompting governments to fund telemedicine hubs and AI triage to extend reach. Arkansas illustrated scalable coverage using statewide teleretinal screening linked to urban retina centers, an approach now copied in Latin America and South Asia.

High Treatment Burden & Poor Adherence to Injection Regimens

Real-world audits find 46% of diabetic macular edema patients discontinue anti-VEGF therapy at least once, twice the dropout seen in age-related macular degeneration. Monthly office visits, cost, and co-morbidities all undermine adherence. Continuous delivery reservoirs such as Susvimo, extended-interval Eylea HD, and one-time RGX-314 gene therapy aim to relieve this burden and are already showing superior durability in trials.

*Our forecasts treat driver/restraint impacts as directional, not additive. The impact forecasts reflect baseline growth, mix effects, and variable interactions.

Segment Analysis

By Type: Non-Proliferative Dominance Drives Early Intervention

Non-proliferative disease accounted for 62.74% diabetic retinopathy market share in 2025, underscoring the impact of screening that now captures pathology earlier. AI systems detecting subtle micro-aneurysms push more patients into preventive care pathways rather than late-stage surgery. Proliferative cases, although smaller, will rise at 7.12% CAGR as aging and disease duration fuel advanced pathology, expanding demand for surgery and regenerative therapies.

Clinical management differs sharply. Non-proliferative patients benefit from systemic agents such as fenofibrate, which cut progression by 27% in trials. Proliferative disease increasingly involves vitrectomy, the fastest-growing modality at 7.88% CAGR. Early gene therapy data show 2-step DRSS improvement in 20% of treated non-proliferative patients, suggesting future disease-stage-specific regimens. The diabetic retinopathy market size for proliferative interventions is projected to outpace overall growth despite the segment鈥檚 current smaller base.

By Management Approach: Anti-VEGF Leadership Faces Sustained-Release Disruption

Anti-VEGF drugs held 55.62% of the diabetic retinopathy market size in 2025 on entrenched physician familiarity and wide-ranging guideline support . The segment is pivoting toward durability. Susvimo鈥檚 reservoir requires two refills a year, and Vabysmo offers dual-pathway inhibition, both carving share from monthly injectables.

Vitrectomy volume will expand fastest at 7.88% CAGR as surgeons treat complex tractional detachments in proliferative disease, with Japan reporting 97.3% single-surgery success. Steroid implants fill a niche for inflammation-driven edema, lowering injection frequency from 4.7 to 1.4 annually. Laser photocoagulation remains useful in combination protocols; meta-analyses show ranibizumab plus laser yields better vision than monotherapy in select cases. Overall, the diabetic retinopathy market continues to shift from frequent injections toward longer-lasting biologics, surgery, and, eventually, one-time gene therapy.

By End-User: Hospital Dominance Shifts Toward Specialized Clinic Growth

Hospitals commanded 51.02% share of the diabetic retinopathy market in 2025 thanks to operating-room access for vitrectomy and multi-disciplinary management of co-morbidities. Procedure-heavy proliferative cases solidify hospital strength, yet cost pressures encourage migration to outpatient settings.

Ophthalmology clinics will grow at 7.43% CAGR, boosted by consolidation that creates nationwide retinal care networks, such as Cencora鈥檚 USD 5.1 billion purchase of Retina Consultants of America. Ambulatory surgical centers gain momentum as sustained-release devices like Susvimo can be implanted in minor-procedure suites. AI screening now launches in primary-care offices, routing positive cases to clinic-based retina specialists, broadening the referral funnel. These shifts produce a more distributed care model while maintaining hospital dominance for the most complex surgeries.

Geography Analysis

North America captured 42.98% of diabetic retinopathy market share in 2025, supported by early adoption of FDA-cleared AI devices, fast biosimilar uptake, and generous payer coverage. The region hosts 71.15% of global diabetic eye research publications from 2012-2021, reinforcing its innovation leadership. A looming 30% shortfall in ophthalmologist supply by 2035 tempers growth, particularly in rural areas, and fuels demand for tele-retina solutions.

Asia-Pacific is expected to grow at 7.95% CAGR through 2031, the highest of all regions, propelled by diabetes incidence and large population bases. China鈥檚 diabetic retinopathy prevalence up to 43.1% among diabetics underscores the region鈥檚 unmet need. India鈥檚 plan to screen 1 billion eyes with AI-enabled handheld cameras highlights large-scale digital health adoption. Government reimbursement expansion and rising medical tourism further spur growth.

Europe demonstrates steady growth on the strength of robust universal health systems and swift biosimilar integration. Latin America leverages tele-ophthalmology, exemplified by Chile鈥檚 network that detects retinopathy in 22% of screened diabetics while cutting unnecessary referrals. The Middle East and Africa remain nascent but attractive due to high diabetes prevalence in Gulf states and incremental investment in specialty care infrastructure.

Regulatory Landscape

Regulation in diabetic retinopathy covers drug, device, and drug-device combination pathways, with sustained-delivery platforms a key focus. In the United States, the FDA Office of Combination Products assigns oversight based on the primary mode of action (PMOA), routing review to CDER/CBER/CDRH and applying combination-product expectations, including human factors and usability evidence for delivery systems. A recent U.S. anchor is the May 2025 FDA approval of Genentech's Susvimo (ranibizumab injection) 100 mg/mL for diabetic retinopathy via an ocular implant, which reinforces the need to coordinate drug and implant lifecycle requirements within a single product strategy.

In Europe, products used in combination with a medical device are reviewed under EU medicines legislation and the Medical Devices Regulation (EU) 2017/745 (MDR), depending on principal mode of action. Since 26 May 2021, MDR Article 117 has required integral drug-device combinations to demonstrate that the device component meets applicable General Safety and Performance Requirements, often adding notified-body style evidence into the marketing authorization dossier. For port delivery systems, implants, and other integral delivery components used with anti-VEGF and emerging therapies, this increases documentation demands and post-market change-control complexity.

Value Chain Analysis

The value chain starts with discovery and clinical development of anti-VEGF biologics, steroids, and emerging modalities, including gene therapy. It then moves through specialized manufacturing, regulatory release, distribution, and administration across hospitals, ophthalmology clinics, and ambulatory surgical centers. For drug-device combinations, the chain also includes device engineering, component sourcing (such as polymer matrices for biodegradable implants), precision manufacturing of applicators and implants, and integrated quality systems that support combination-product submissions. Downstream administration and follow-up matter as well, since intravitreal therapy depends on cold-chain distribution for biologics, inventory management at retinal practices, and procedure capacity that is constrained by retinal specialist availability in multiple regions.

Recent activity points to convergence around durability-focused delivery platforms. In March 2026, Chugai Pharmaceutical filed in Japan for the medical device component of the Port Delivery Platform with ranibizumab, which underscores the need for parallel regulatory and manufacturing planning for the hardware and drug payload. Biosimilar dynamics also affect sourcing and commercialization. Developments such as the February 2026 FDA approval of an indication extension for Sandoz's aflibercept biosimilar Enzeevu to include diabetic retinopathy intensify competition and shift differentiation toward proprietary delivery systems, service-network scale, and procedure throughput.

Market Opportunities and Future Outlook

Treatment durability and reduced visit burden are the most visible whitespace areas, with the base of support coming from completed regulatory actions and active pipeline programs rather than incremental formulation changes. The May 2025 FDA approval of Genentech's Susvimo for diabetic retinopathy established continuous delivery as a commercial option, creating a clearer path for competing sustained-release platforms (ports and bio-erodible implants) and associated procedure workflows in hospitals and outpatient settings. Another opportunity is one-time or infrequent therapies that can address adherence challenges seen in real-world anti-VEGF regimens, where discontinuation remains a documented constraint across markets.

Pipeline investment and late-stage trial initiation further indicate where development spending is concentrating. In June 2026, REGENXBIO initiated the Phase IIb/III NAAVIGATE trial of surabgene lomparvovec (sura-vec) for non-proliferative diabetic retinopathy via suprachoroidal delivery, signaling continued build-out of gene-therapy delivery and clinical infrastructure beyond intravitreal injections. On the platform side, Bayer's agreement to acquire Perfuse Therapeutics for up to USD 2.45 billion (announced in May 2026) underscores strategic interest in implant-based approaches for diabetic retinopathy and expands the partnering space across implant materials, device manufacturing, and retina-provider networks needed to scale sustained-delivery therapies.